Information Provided By:
Fly News Breaks for September 9, 2015
TTPH
Sep 9, 2015 | 05:43 EDT
Brean Capital analyst Jonathan Aschoff downgraded Tetraphase Pharmaceuticals to Hold after eravacycline did not achieve its primary endpoint in a Phase 3 study. Aschoff wants to wait on the sidelines until a "clearer path forward emerges." JMP Securities also downgraded Tetraphase this morning.
News For TTPH From the Last 2 Days
There are no results for your query TTPH